Back HCV Treatment

HCV Treatment

May Is Hepatitis Awareness Month

May is Hepatitis Awareness Month in the U.S., an opportunity to promote better understanding of viral hepatitis and to encourage more people to get tested and receive care for hepatitis B and C. Hepatitis Testing Day is coming up on May 19.

alt

Read more:

EASL 2014: Sofosbuvir + Ribavirin Is Safe and Effective for HCV Recurrence after Liver Transplant

An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to a poster presented at the 49thEASL International Liver Congress (EASL 2014) held recently in London.

alt

Read more:

Achillion Announces Start of Studies of ACH-3422 and ACH-3102 for Hepatitis C

Achillion Pharmaceuticalsannounced this week that the first participants have started receiving treatment in a Phase 1 clinical trial testing the investigational nucleotide hepatitis C virus (HCV) polymerase inhibitor ACH-3422. In addition, a recently initiated Phase 2 study is evaluating the company's next-generation NS5A inhibitor ACH-3012 in combination with Gilead Sciences' sofosbuvir (Sovaldi) for as little as 8 or even 6 weeks.

alt

Read more:

EASL 2014: VX-135 + Daclatasvir Shows Modest Cure Rate in Phase 2 Study

Treatment with an interferon-free regimen of daclatasvir plus VX-135 for 12 weeks was safe and well-tolerated for genotype 1 chronic hepatitis C patients, but the sustained virological response rate of 83% for easier-to-treat patients did not stand up well to cure rates of 90% or higher seen with other similar combinations, according to a late-breaker poster presented at the 49thEASL International Liver Congress held recently in London.

alt

Read more:

EASL 2014: Sustained Response to Treatment Reduces Fatigue in Hepatitis C Patients

Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most problematic symptoms associated with chronic hepatitis C, according to research presented at the EASL Liver International Liver Congressthis month in London.

alt

Read more: